Ares Financial Consulting
GPCR icon

Ares Financial Consulting’s Structure Therapeutics GPCR Stock Holding History

Ares Financial Consulting’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-20
Closed -$1.07K – 1099
2026
Q2 		$1.07K Buy
+20
New +$885 ﹤0.01% 997

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Capitolis Liquid Global Markets
Capitolis Liquid Global Markets New York $22.4B AUM 40.52% 1-Year Est. Return
Pacific Heights Asset Management
Pacific Heights Asset Management San Francisco, California $3.1B AUM 37.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Ares Financial Consulting's GPCR Position: Q3 2026 in Review

Ares Financial Consulting sold out of Structure Therapeutics (GPCR) in Q3 2026, closing a stake of 20 shares — an estimated $1.07K sold.

Ares Financial Consulting first reported a position in GPCR in Q2 2026 and held it in 1 quarter. The position peaked at $1.07K in Q2 2026. 113 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

  • Ares Financial Consulting reported no remaining Structure Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Ares Financial Consulting sold 20 Structure Therapeutics shares in Q3 2026, an estimated $1.07K.
  • Ares Financial Consulting first reported a position in Structure Therapeutics in Q2 2026 and held it in 1 quarter.
  • Ares Financial Consulting's Structure Therapeutics position peaked at $1.07K in Q2 2026.
  • 113 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.